Literature DB >> 16419625

Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee.

Mario Sideri1, Ronald W Jones, Edward J Wilkinson, Mario Preti, Debra S Heller, James Scurry, Hope Haefner, Sallie Neill.   

Abstract

In the current classification, squamous vulvar intraepithelial neoplasia (VIN) is categorized as VIN 1, 2 and 3 according to the degree of abnormality. There is neither evidence that the VIN 1-3 morphologic spectrum reflects a biologic continuum nor that VIN 1 is a cancer precursor. The VIN 2 and 3 category includes 2 types of lesion, which differ in morphology, biology and clinical features. VIN, usual type (warty, basaloid and mixed), is HPV related in most cases. Invasive squamous carcinomas of warty or basaloid type is associated with VIN, usual type. VIN, differentiated type, is seen particularly in older women with lichen sclerosus and/or squamous cell hyperplasia in some cases. Neither VIN, differentiated type, nor associated keratinizing squamous cell carcinoma is HPV related. The term VIN should apply only to histologically high grade squamous lesions (former terms, VIN 2 and VIN 3 and differentiated VIN 3). The term VIN 1 will no longer be used. Two categories should describe squamous VIN: VIN, usual type (encompassing former VIN 2 and 3 of warty, basaloid and mixed types) and VIN, differentiated type (VIN 3, differentiated type).

Entities:  

Mesh:

Year:  2005        PMID: 16419625

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  45 in total

Review 1.  Medical interventions for high grade vulval intraepithelial neoplasia.

Authors:  Litha Pepas; Sonali Kaushik; Andrew Bryant; Andy Nordin; Heather O Dickinson
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

2.  Labia Majora Share.

Authors:  Hanjing Lee; Yan Lin Yap; Jeffrey Jen Hui Low; Jane Lim
Journal:  Arch Plast Surg       Date:  2017-01-20

3.  Diagnosis, Therapy and Follow-up Care of Vulvar Cancer and its Precursors. Guideline of the DGGG and DKG (S2k-Level, AWMF Registry Number 015/059, November 2015.

Authors:  H G Schnürch; S Ackermann; C D Alt; J Barinoff; C Böing; C Dannecker; F Gieseking; A Günthert; P Hantschmann; L C Horn; R Kürzl; P Mallmann; S Marnitz; G Mehlhorn; C C Hack; M C Koch; U Torsten; W Weikel; L Wölber; M Hampl
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-10       Impact factor: 2.915

Review 4.  EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease.

Authors:  Marc Arbyn; Silvia de Sanjosé; Mona Saraiya; Mario Sideri; Joel Palefsky; Charles Lacey; Maura Gillison; Laia Bruni; Guglielmo Ronco; Nicolas Wentzensen; Julia Brotherton; You-Lin Qiao; Lynnette Denny; Jacob Bornstein; Laurent Abramowitz; Anna Giuliano; Massimo Tommasino; Joseph Monsonego
Journal:  Int J Cancer       Date:  2012-07-02       Impact factor: 7.396

Review 5.  [HPV-associated alterations of the vulva and vagina. Morphology and molecular pathology].

Authors:  L-C Horn; K Klostermann; S Hautmann; A K Höhn; M W Beckmann; G Mehlhorn
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

6.  Coexisting high-grade vulvar intraepithelial neoplasia (VIN) and condyloma acuminatum: independent lesions due to different HPV types occurring in immunocompromised patients.

Authors:  Kruti P Maniar; Brigitte M Ronnett; Russell Vang; Anna Yemelyanova
Journal:  Am J Surg Pathol       Date:  2013-01       Impact factor: 6.394

7.  Expression profiling of vulvar carcinoma: clues for deranged extracellular matrix remodeling and effects on multiple signaling pathways combined with discrete patient subsets.

Authors:  Kalliopi I Pappa; Jasmine Jacob-Hirsch; George D Vlachos; Ioanna Christodoulou; George Partsinevelos; Ninette Amariglio; Sofia Markaki; Aris Antsaklis; Nicholas P Anagnou
Journal:  Transl Oncol       Date:  2011-10-01       Impact factor: 4.243

8.  Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.

Authors:  Joakim Dillner; Susanne K Kjaer; Cosette M Wheeler; Kristján Sigurdsson; Ole-Erik Iversen; Mauricio Hernandez-Avila; Gonzalo Perez; Darron R Brown; Laura A Koutsky; Eng Hseon Tay; Patricia García; Kevin A Ault; Suzanne M Garland; Sepp Leodolter; Sven-Eric Olsson; Grace W K Tang; Daron G Ferris; Jorma Paavonen; Matti Lehtinen; Marc Steben; F Xavier Bosch; Elmar A Joura; Slawomir Majewski; Nubia Muñoz; Evan R Myers; Luisa L Villa; Frank J Taddeo; Christine Roberts; Amha Tadesse; Janine T Bryan; Roger Maansson; Shuang Lu; Scott Vuocolo; Teresa M Hesley; Eliav Barr; Richard Haupt
Journal:  BMJ       Date:  2010-07-20

Review 9.  Vulvar lichen sclerosus in the elderly: pathophysiology and treatment update.

Authors:  Natalie A Saunders; Hope K Haefner
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

10.  Patients with usual vulvar intraepithelial neoplasia-related vulvar cancer have an increased risk of cervical abnormalities.

Authors:  R P de Bie; H P van de Nieuwenhof; R L M Bekkers; W J G Melchers; A G Siebers; J Bulten; L F A G Massuger; J A de Hullu
Journal:  Br J Cancer       Date:  2009-06-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.